-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Investors in Prometheus Biosciences (NASDAQ:RXDX) Have Made a Splendid Return of 262% Over the Past Year
Investors in Prometheus Biosciences (NASDAQ:RXDX) Have Made a Splendid Return of 262% Over the Past Year
Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares in, you can make more than you can lose. For example, the Prometheus Biosciences, Inc. (NASDAQ:RXDX) share price has soared 262% in the last 1 year. Most would be very happy with that, especially in just one year! Also pleasing for shareholders was the 112% gain in the last three months. Prometheus Biosciences hasn't been listed for long, so it's still not clear if it is a long term winner.
Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.
View our latest analysis for Prometheus Biosciences
Prometheus Biosciences wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
Over the last twelve months, Prometheus Biosciences' revenue grew by 182%. That's a head and shoulders above most loss-making companies. And the share price has responded, gaining 262% as we previously mentioned. That sort of revenue growth is bound to attract attention, even if the company doesn't turn a profit. Given the positive sentiment around the stock we're cautious, but there's no doubt its worth watching.
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
Prometheus Biosciences is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. If you are thinking of buying or selling Prometheus Biosciences stock, you should check out this free report showing analyst consensus estimates for future profits.
A Different Perspective
It's nice to see that Prometheus Biosciences shareholders have gained 262% over the last year. And the share price momentum remains respectable, with a gain of 112% in the last three months. Demand for the stock from multiple parties is pushing the price higher; it could be that word is getting out about its virtues as a business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 3 warning signs for Prometheus Biosciences you should be aware of, and 1 of them shouldn't be ignored.
We will like Prometheus Biosciences better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
不幸的是,投资是有风险的--公司可能而且确实会破产。但如果你选择了正确的企业来购买股票,你可以赚得比失去的多。例如,普罗米修斯生物科学公司纳斯达克(Sequoia Capital:RXDX)股价在过去一年里飙升了262%。大多数人会对此感到非常高兴,特别是在短短一年内!同样令股东高兴的是,过去三个月的涨幅为112%。普罗米修斯生物科学公司上市时间不长,因此目前还不清楚它是否是长期的赢家。
现在也有必要看看该公司的基本面,因为这将有助于我们确定长期股东回报是否与基础业务的表现相匹配。
查看我们对普罗米修斯生物科学的最新分析
普罗米修斯生物科学公司在过去的12个月里没有盈利,我们不太可能看到它的股价和每股收益(EPS)之间有很强的相关性。可以说,收入是我们的下一个最佳选择。未盈利公司的股东通常预期营收增长强劲。正如你可以想象的那样,快速的收入增长,如果保持下去,往往会带来快速的利润增长。
在过去的12个月里,普罗米修斯生物科学公司的收入增长了182%。这远远超过了大多数亏损的公司。股价做出了回应,正如我们之前提到的那样,上涨了262%。这种营收增长势必会引起人们的注意,即使该公司不会盈利。考虑到围绕该股的积极情绪,我们持谨慎态度,但毫无疑问,它值得关注。
该公司的收入和收益(随着时间的推移)如下图所示(点击查看具体数字)。
普罗米修斯生物科学公司为投资者所熟知,许多聪明的分析师曾试图预测未来的利润水平。如果你正在考虑购买或出售普罗米修斯生物科学公司的股票,你应该看看这个免费显示分析师对未来利润的一致估计的报告。
不同的视角
很高兴看到普罗米修斯生物科学公司的股东在过去一年中获得了262%的收益。股价势头依然可观,在过去三个月中上涨了112%。多方对该股的需求正在推高股价;可能是因为有消息称,该公司作为一家企业的优点正在流传开来。我发现,把股价作为衡量企业业绩的长期指标是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。一个恰当的例子:我们发现了普罗米修斯生物科学的3个警告信号你应该意识到,其中有一个是不应该被忽视的。
如果我们看到一些大的内部收购,我们会更喜欢普罗米修斯生物科学公司。在我们等待的时候,看看这个免费最近有大量内幕收购的成长型公司名单。
请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。
对这篇文章有什么反馈吗?担心内容吗?保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧